BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy 2017;19:293-8. [PMID: 27956199 DOI: 10.1016/j.jcyt.2016.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma C, Wang Z, Xu T, He Z, Wei Y. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances 2020;40:107502. [DOI: 10.1016/j.biotechadv.2019.107502] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 73.0] [Reference Citation Analysis]
2 Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev 2021;22:11-4. [PMID: 34377737 DOI: 10.1016/j.omtm.2021.06.012] [Reference Citation Analysis]
3 Spinner DS, Faulkner EC, Carroll MC, Ringo MC, Joines JW. Regenerative Medicine and Cell Therapy in Orthopedics—Health Policy, Regulatory and Clinical Development, and Market Access. Techniques in Orthopaedics 2019;34:224-43. [DOI: 10.1097/bto.0000000000000413] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yahya EB, Alqadhi AM. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sci 2021;269:119087. [PMID: 33476633 DOI: 10.1016/j.lfs.2021.119087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
5 Qiu T, Wang Y, Liang S, Han R, Toumi M. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. Drug Discov Today 2021:S1359-6446(21)00207-5. [PMID: 33892148 DOI: 10.1016/j.drudis.2021.04.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 van Overbeeke E, Hauber B, Michelsen S, Peerlinck K, Lambert C, Hermans C, Lê PQ, Goldman M, Simoens S, Huys I. Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. Haemophilia 2021;27:957-66. [PMID: 34472162 DOI: 10.1111/hae.14401] [Reference Citation Analysis]
7 van Overbeeke E, Michelsen S, Toumi M, Stevens H, Trusheim M, Huys I, Simoens S. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021;26:399-415. [PMID: 33242695 DOI: 10.1016/j.drudis.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7:676-685. [PMID: 30063299 DOI: 10.1002/sctm.17-0282] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 22.0] [Reference Citation Analysis]
9 Rach C, Lukas J, Müller R, Sendler M, Simon P, Salloch S. Involving Patient Groups in Drug Research: A Systematic Review of Reasons. Patient Prefer Adherence 2020;14:587-97. [PMID: 32210544 DOI: 10.2147/PPA.S232499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]